Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents
- Author
- Charlotte Courtens, Frits van Charante, Thibaut Quennesson (UGent) , Martijn Risseeuw (UGent) , Paul Cos, Guy Caljon, Tom Coenye (UGent) and Serge Van Calenbergh (UGent)
- Organization
- Project
-
- Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectives
- Synthesis of a-GalCer analogues as tools to elucidate the mechanisms of NKT cell polarization.
- Collaboromics: identifying and engineering core and satellite populations in (synthetic) microbial ecosystems
- Abstract
- Fosmidomycin is a natural antibiotic with potent IspC (DXR, 1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitory activity. This enzyme catalyzes the first committed step of the non-mevalonate isoprenoid biosynthesis pathway, which is essential in most bacteria, including A. baumanii and M. tuberculosis, and apicomplexan parasites, including Plasmodium parasites. Mainly as a result of its high polarity, fosmidomycin displays suboptimal pharmacokinetic properties. Furthermore, fosmidomycin is inactive against A. baumannii and M. tuberculosis as a result of its inability to penetrate the bacterial cell wall. Temporarily masking the phosphonate moiety as a prodrug has the potential to solve both issues. We report on the expansion of the acyloxymethyl and alkoxycarbonyloxymethyl phosphonate ester prodrug series of a fosmidomycin surrogate. Prodrug promoieties were designed based on electronic, lipophilic and siderophoric properties. This investigation led to the discovery of derivatives with two-digit nanomolar and submicromolar IC50-values against P. falciparum and A. baumanii, respectively.
- Keywords
- Fosmidomycin, Prodrugs, Isoprenoid biosynthesis, Malaria, Tuberculosis, ESKAPE, METHYLERYTHRITOL PHOSPHATE-PATHWAY, FR900098, SIDEROPHORE, DERIVATIVES, INHIBITION, ANALOGS, ESTERS
Downloads
-
EJMC CC 2022 R1 final.docx
- full text (Accepted manuscript)
- |
- open access
- |
- Word
- |
- 569.41 KB
-
SI combined 1 final.pdf
- supplementary material
- |
- open access
- |
- |
- 7.33 MB
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 1.11 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HE012S7K6B9YCARV7TP208PY
- MLA
- Courtens, Charlotte, et al. “Acyloxymethyl and Alkoxycarbonyloxymethyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antibacterial Agents.” EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 245, no. 1, 2023, doi:10.1016/j.ejmech.2022.114924.
- APA
- Courtens, C., van Charante, F., Quennesson, T., Risseeuw, M., Cos, P., Caljon, G., … Van Calenbergh, S. (2023). Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 245(1). https://doi.org/10.1016/j.ejmech.2022.114924
- Chicago author-date
- Courtens, Charlotte, Frits van Charante, Thibaut Quennesson, Martijn Risseeuw, Paul Cos, Guy Caljon, Tom Coenye, and Serge Van Calenbergh. 2023. “Acyloxymethyl and Alkoxycarbonyloxymethyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antibacterial Agents.” EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 245 (1). https://doi.org/10.1016/j.ejmech.2022.114924.
- Chicago author-date (all authors)
- Courtens, Charlotte, Frits van Charante, Thibaut Quennesson, Martijn Risseeuw, Paul Cos, Guy Caljon, Tom Coenye, and Serge Van Calenbergh. 2023. “Acyloxymethyl and Alkoxycarbonyloxymethyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antibacterial Agents.” EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 245 (1). doi:10.1016/j.ejmech.2022.114924.
- Vancouver
- 1.Courtens C, van Charante F, Quennesson T, Risseeuw M, Cos P, Caljon G, et al. Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2023;245(1).
- IEEE
- [1]C. Courtens et al., “Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents,” EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 245, no. 1, 2023.
@article{01HE012S7K6B9YCARV7TP208PY,
abstract = {{Fosmidomycin is a natural antibiotic with potent IspC (DXR, 1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitory activity. This enzyme catalyzes the first committed step of the non-mevalonate isoprenoid biosynthesis pathway, which is essential in most bacteria, including A. baumanii and M. tuberculosis, and apicomplexan parasites, including Plasmodium parasites. Mainly as a result of its high polarity, fosmidomycin displays suboptimal pharmacokinetic properties. Furthermore, fosmidomycin is inactive against A. baumannii and M. tuberculosis as a result of its inability to penetrate the bacterial cell wall. Temporarily masking the phosphonate moiety as a prodrug has the potential to solve both issues. We report on the expansion of the acyloxymethyl and alkoxycarbonyloxymethyl phosphonate ester prodrug series of a fosmidomycin surrogate. Prodrug promoieties were designed based on electronic, lipophilic and siderophoric properties. This investigation led to the discovery of derivatives with two-digit nanomolar and submicromolar IC50-values against P. falciparum and A. baumanii, respectively.}},
articleno = {{114924}},
author = {{Courtens, Charlotte and van Charante, Frits and Quennesson, Thibaut and Risseeuw, Martijn and Cos, Paul and Caljon, Guy and Coenye, Tom and Van Calenbergh, Serge}},
issn = {{0223-5234}},
journal = {{EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY}},
keywords = {{Fosmidomycin,Prodrugs,Isoprenoid biosynthesis,Malaria,Tuberculosis,ESKAPE,METHYLERYTHRITOL PHOSPHATE-PATHWAY,FR900098,SIDEROPHORE,DERIVATIVES,INHIBITION,ANALOGS,ESTERS}},
language = {{eng}},
number = {{1}},
pages = {{14}},
title = {{Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents}},
url = {{http://doi.org/10.1016/j.ejmech.2022.114924}},
volume = {{245}},
year = {{2023}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: